HopeStage
Back to all studies
CompletedNCT00000297

Labetalol and the body's response to nicotine

About this titleRead the official source — NCT00000297
Medication studyAges 21–55United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 21 years to 55 years.

Listed locations
MinneapolisSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 1998
Recruitment status
Completed
Enrollment listed in the registry
0
Sponsor
National Institute on Drug Abuse (NIDA)
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 21 Years to 55 Years
Official registry ID
NCT00000297
Official title
Show the full official title

Effects of Labetalol on Nicotine Administration in Humans

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Minneapolis

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is National Institute on Drug Abuse (NIDA), a research institute.

Did this study involve medication?

Yes. The study involved medication, including Labetalol.

Who was this study for?

Listed age limits: 21 years to 55 years.

Want to explore more studies?

Explore studies